Slingshot members are tracking this event:
Agios Pharma (AGIO) to complete Phase 1 study of AG-519 in Patients With Pyruvate Kinase Deficiency in September 2016
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Jun 09, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Pyruvate Kinase Deficiency, Pk Deficiency, Phase 1 Study, Ag-519, Double Blind